# BPC-157: research overview | Peptide Research Alliance > BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid research peptide. Most evidence is from animal studies; human data are limited. Plain-English summary of mechanism, findings, and safety cautions. A repair peptide with a large animal-study database and a very thin human evidence base. Here is what the literature actually shows. ## The short version BPC-157 stands for Body Protection Compound 157. It is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice — the stomach's own protective lining gave rise to this molecule. In animal models, it consistently promotes healing of tendons, ligaments, gut tissue, and bone, primarily through promoting the growth of new blood vessels. Here is the important context: almost everything known about BPC-157 comes from rodent studies. As of 2025, published reviews count only a handful of small, uncontrolled human pilot reports — no large, rigorous, controlled human trials have been completed [9]. A 2025 first-in-human IV safety pilot involved just two adult participants and found no adverse events, but it was not an efficacy trial [8]. BPC-157 is not approved as a medicine anywhere. It is sold for laboratory research use only. The FDA placed it in a category of substances identified as not eligible for pharmacy compounding pending further evaluation. Athletes should note it is prohibited by WADA at all times. ## What it is BPC-157's full name is Body Protection Compound 157. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — fifteen residues long. Research designations include PL 14736, PLD-116, and Bepecin. Molecular formula: C62H98N16O22. The peptide is stable in both acidic and basic environments, which distinguishes it from most peptides and gives it activity when taken orally in animal models. Its pharmacokinetics in animals: a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14–51% depending on species), and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [10]. No human pharmacokinetic study exists. ## How it works The best-characterized mechanism is **pro-angiogenic**: BPC-157 upregulates and promotes internalization of VEGFR2 (the main vascular endothelial growth factor receptor), with downstream activation of the VEGFR2-Akt-eNOS pathway. This increases the formation of new blood vessels — a plausible route to faster tissue repair in models of tendon, gut, and ischemic-muscle injury [11]. Additional proposed pathways include: - **FAK-paxillin signaling**, which governs cell migration during wound healing. - **Growth-hormone receptor sensitization** in tendon fibroblasts, which could explain some of the musculoskeletal findings. - **Nitric-oxide system modulation**, which has downstream effects on blood flow and tissue tone. - **Neurotransmitter-system interactions**, particularly with serotonin — an observation that carries a caution around concurrent use with serotonergic medications. No single receptor has been confirmed as a primary binding target for BPC-157; it is not a conventional receptor agonist but rather seems to act through downstream signaling cascades. ## What the research shows **Foundational gastric protection (2004):** In rats, BPC-157 reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming the oral route. This was among the original demonstrations of the peptide's cytoprotective activity that gave it its name [12]. **VEGFR2 and angiogenesis (2017):** Using chick chorioallantoic membrane, rat hindlimb ischemia models, and human vascular endothelial cells, researchers demonstrated that BPC-157's pro-angiogenic effects depend on VEGFR2 upregulation and internalization — effects that were blocked when endocytosis was inhibited. This is currently the most mechanistically well-supported finding in the literature [11]. **Pharmacokinetics (2022):** The first formal pharmacokinetic characterization showed linear, dose-proportional kinetics; elimination half-life under 30 minutes; intramuscular bioavailability ~14–51% across species; and excretion via urine and bile. This helps explain why route and frequency of administration matter in animal models [10]. **2025 narrative review:** A review published in *Current Reviews in Musculoskeletal Medicine* concluded that only three human pilot studies exist, rigorous large-scale controlled trials are lacking, and BPC-157 should be considered investigational. It explicitly flags that the large share of foundational literature originates from a single research group (limiting independent replication) [9]. **First-in-human IV pilot (2025):** Two adult participants (ages 58 and 68) received intravenous BPC-157 up to 20 mg. No adverse events were observed; no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers occurred. The study's authors describe it as a safety pilot, not an efficacy trial — and with two participants, no safety conclusions can be generalized [8]. ## Reported effects, cautions & safety **What research-use communities report** *(anecdotal, not clinical evidence — personal accounts from people using unregulated material; no confirmed doses, no clinical oversight)* The main driver of BPC-157 community interest is reported faster recovery from tendon, ligament, and joint injuries — stubborn problems like tennis elbow, rotator-cuff strains, and old sprains that people describe resolving or becoming more usable, often within the first few weeks. Many also report reduced joint stiffness and less day-to-day pain. Gut-symptom improvement is frequently mentioned — less bloating, cramping, and urgency — which makes sense given the peptide's origin in gastric-protective research. Injection-site redness and brief stinging are the most consistently mentioned adverse reports; mild nausea and initial fatigue are also commonly noted. **Safety cautions from the literature:** *Thin human evidence:* The honest position, supported by 2025 reviews, is that the balance of benefit and risk in humans is genuinely unknown. Animal results cannot be read as proven benefits in people [9]. *One-group dominance:* A large share of the BPC-157 literature was produced by a single research group, limiting independent replication. Newer reviewers explicitly flag this [9]. *Unregulated supply:* BPC-157 is not approved as a medicine anywhere. Products sold through non-regulated channels have no verified identity, purity, or dose [9]. *Pro-angiogenic signal and cancer:* BPC-157's repair effects are tied to angiogenesis via VEGFR2 and the nitric-oxide system [11]. Because tumors also depend on angiogenesis to grow, there is a theoretical concern about using a strongly pro-angiogenic agent in anyone with active or suspected cancer. This is mechanism-based reasoning, not a documented human harm. *Serotonin-system interaction:* Rodent work shows BPC-157 alters brain serotonin activity. A mechanism-based caution about combining it with serotonin-affecting medications (such as certain antidepressants) applies, based on animal data only. *WADA prohibition:* BPC-157 is banned in sport at all times under the S0 non-approved-substances category. ## Where it fits BPC-157 occupies the most preclinical position of the five compounds covered here. Its animal-study database is large and internally consistent — but the 2025 literature explicitly reminds readers that only a handful of human participants have been studied in any capacity [9]. That gap between animal enthusiasm and human evidence is the defining feature of its current status. It is not a growth hormone, not a steroid, and not a conventional receptor agonist — a common source of confusion in community discussions. Its proposed mechanism is angiogenic and cytoprotective, not hormonal in the GH-axis sense. For readers following this compound, independent human trials are what the evidence base currently needs most. --- An independent literature desk where every enthusiastic claim is immediately grounded in a citation and every gap in the evidence is stated plainly.